Mwanzo4AB • ETR
add
AbbVie Inc
Bei iliyotangulia
€ 174.56
Bei za siku
€ 173.00 - € 174.24
Bei za mwaka
€ 125.50 - € 192.50
Thamani ya kampuni katika soko
323.53B USD
Wastani wa hisa zilizouzwa
elfu 1.18
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NYSE
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 14.46B | 3.83% |
Matumizi ya uendeshaji wa biashara | 6.07B | 21.67% |
Mapato halisi | 1.56B | -12.20% |
Kiwango cha faida halisi | 10.80 | -15.43% |
Mapato kwa kila hisa | 3.00 | 1.69% |
EBITDA | 6.26B | -8.02% |
Asilimia ya kodi ya mapato | 24.95% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 7.28B | -45.18% |
Jumla ya mali | 143.42B | 5.29% |
Jumla ya dhima | 137.35B | 10.68% |
Jumla ya hisa | 6.07B | — |
hisa zilizosalia | 1.77B | — |
Uwiano wa bei na thamani | 51.19 | — |
Faida inayotokana na mali | 7.33% | — |
Faida inayotokana mtaji | 13.48% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.56B | -12.20% |
Pesa kutokana na shughuli | 5.45B | -28.08% |
Pesa kutokana na uwekezaji | -8.26B | -2,137.40% |
Pesa kutokana na ufadhili | -3.07B | -15.45% |
Mabadiliko halisi ya pesa taslimu | -5.87B | -229.70% |
Mtiririko huru wa pesa | 5.50B | -26.01% |
Kuhusu
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Ilianzishwa
1 Jan 2013
Makao Makuu
Tovuti
Wafanyakazi
50,000
